While Roche, Lilly and Merck push on aggressively, Novartis throws in the towel.

Readouts for Lilly and Pfizer/Arvinas loom, but many SERD hopefuls are now focused on earlier-stage breast cancer.

The group reaffirms pancreatic cancer promise with RMC-6236, but has it found the best dose?

After Tacti-003’s controlled cohorts fail, Immutep plays up single-arm data in PD-L1 non-expressers.

Meanwhile, Torl BioTherapeutics appears to be catching up with BioNTech.

Micromet’s tech has yielded two marketed drugs, one still in the clinic... and 14 discontinuations.